Objectives: To investigate whether cerebrospinal fluid (CSF) biomarkers of neurodegeneration are altered in narcolepsy in order to evaluate whether the hypocretin deficiency and abnormal sleep-wake pattern in narcolepsy leads to neurodegeneration. Methods: Twenty-one patients with central hypersomnia (10 type 1 narcolepsy, 5 type 2 narcolepsy, and 6 idiopathic hypersomnia cases), aged 33 years on average and with a disease duration of 2-29 years, and 12 healthy controls underwent CSF analyses of the levels of β-amyloid, total tau protein (T-tau), phosphorylated tau protein (P-tau181), α-synuclein, neurofilament light chain (NF-L), and chitinase 3-like protein-1 (CHI3L1). Results: Levels of β-amyloid were lower in patients with type 1 narcolepsy (375.4 ± 143.5 pg/mL) and type 2 narcolepsy (455.9 ± 65.0 pg/mL) compared to controls (697.9 ± 167.3 pg/mL, p < .05). Furthermore, in patients with type 1 narcolepsy, levels of T-tau (79.0 ± 27.5 pg/mL) and P-tau181 (19.1 ± 4.3 pg/mL) were lower than in controls (162.2 ± 49.9 pg/mL and 33.8 ± 9.2 pg/mL, p < .05). Levels of α-synuclein, NF-L, and CHI3L1 in CSF from narcolepsy patients were similar to those of healthy individuals. Conclusion: Six CSF biomarkers of neurodegeneration were decreased or normal in narcolepsy indicating that taupathy, synucleinopathy, and immunopathy are not prevalent in narcolepsy patients with a disease duration of 2-29 years. Lower CSF levels of β-amyloid, T-tau protein, and P-tau181 in narcolepsy may indicate that hypocretin deficiency and an abnormal sleep-wake pattern alter the turnover of these proteins in the central nervous system.
INTRODUCTION
The existence of sleep throughout the animal kingdom suggests that sleep serves a vital function although it is unclear why it is restorative. 1 Roles for sleep in energy conservation, nervous system recuperation, and emotional regulation have been suggested. 2 Furthermore, sleep may contribute to the processes of memory and brain plasticity. 3 Conversely, sleep deprivation reduces learning, impairs performance in cognitive tests, and slows reaction time. 4 Recently, the sleeping rodent brain has been shown to remove metabolic waste products at a faster rate than during an awake state. 5 In adult mice, natural sleep or anesthesia was associated with increased clearance of interstitial metabolites and proteins, including β-amyloid, via the glymphatic pathway to the blood. [5] [6] [7] [8] [9] Furthermore, the concentration of β-amyloid in brain interstitial fluid (ISF) showed diurnal variation, with higher levels in awake than in sleeping rodents and humans. [10] [11] [12] Hypersomnias of central origin include type 1 narcolepsy with cataplexy and hypocretin deficiency, type 2 narcolepsy without cataplexy, and idiopathic hypersomnia with normal cerebrospinal fluid (CSF) hypocretin level. 13 Type 1 narcolepsy is caused by loss of hypocretin neurons in the lateral hypothalamus, which is reflected by low hypocretin-1 levels in CSF. 14, 15 Narcolepsy without cataplexy shows etiological heterogeneity and hypocretin-1 deficiency in a minority (24%) of patients. 16 Patients suffering from type 1 and type 2 narcolepsy demonstrate disturbed nocturnal sleep with frequent awakenings and fast onset of rapid eye movement (REM) sleep phases, although total sleep time over the 24-hr period is within the normal range. 17, 18 Idiopathic hypersomnia patients are characterized by excessive daytime sleepiness, despite long sleeping hours and normal overnight polysomnography (PSG). 19 An autoimmune mechanism is believed to cause type 1 narcolepsy, whereas the etiology of type 2 narcolepsy and idiopathic hypersomnia is not known. 14, 16, 19 However, the extent to which neurodegenerative mechanisms like those known in taupathies, synucleinopathies, and immunopathies may play a role in the pathology of narcolepsy and idiopathic hypersomnia has been debated. [20] [21] [22] Alzheimer's disease (AD) is characterized in the brain by β-amyloid deposition, neurofibrillary tangle formation (aggregated hyperphosphorylated tau), and extensive neuronal degeneration. 20 The diagnosis of AD is based on clinical assessment and biomarkers including lower β-amyloid and increased total tau (T-tau) and phosphorylated
Statement of Significance
Cerebrospinal fluid biomarkers of neurodegeneration are decreased or normal in narcolepsy, indicating that these patients may have low risk of degenerative or inflammatory processes in the brain. The pathophysiological mechanism behind the lower cerebrospinal fluid levels of β-amyloid, T-tau, and P-tau181 in type 1 narcolepsy is not clear. It is possible that hypocretin deficiency and abnormal sleep-wake pattern alter the turnover of these proteins in the brain. We speculate that the hypocretin deficiency in narcolepsy may reduce β-amyloid release during awakenings and that the abnormal sleep-wake pattern in narcolepsy patients may increase β-amyloid, T-tau, and P-tau181 clearance in the brain. Future research should be directed to study these mechanisms.
tau181 (P-tau181) in CSF. 23 Parkinson's disease (PD) is characterized by intracellular Lewy bodies and progressive deposition of α-synuclein in the brain from the brain stem to other regions, including the amygdala, cingulate gyrus, and higher cortical regions. 21 Biochemically, the diagnosis can be supported by increased α-synuclein in CSF. 24 Multiple sclerosis (MS) is caused by acute and chronic inflammatory processes that disturb neuroaxonal homeostasis and drive neurodegeneration. 22 CSF levels of neurofilament light (NF-L) subunit and the glial marker chitinase 3-like protein-1 (CHI3L1), also known as YKL-40, are increased in MS during relapse and secondary progression. 25, 26 Neurodegenerative diseases are to a varying degree associated with abnormal sleep patterns including insomnia, excessive daytime sleepiness, REM sleep behavior disorder (RBD), narcolepsy-like episodes, circadian changes, sleep-disordered breathing, behavioral problems at sunset (sundowning), nocturnal wandering, vivid dreams, and restless legs syndrome. 27 RBD has become a well-established risk factor for α-synucleinopathies. 28 Sleep-wake problems occur early in AD. 29 Furthermore, the β-amyloid concentration in CSF of humans rises during wakefulness and falls during sleep, that is, an β-amyloid diurnal pattern, suggesting that circadian and sleep disorders may play a role in AD pathogenesis. 30, 31 Recently, interactions between the amyloid process in AD and the sleepwake switching system have been proposed. CSF hypocretin-1 levels were higher in patients with AD and mild cognitive impairment (MCI) compared to other dementias, with a similar tendency for patients with advanced AD. 32, 33 Decreased CSF levels of β-amyloid have been reported in type 1 and type 2 narcolepsy, whereas levels of T-tau and P-tau181 did not differ from those in controls. 34 In contrast, another study found higher CSF levels of β-amyloid, T-tau, and P-tau181 in type 1 and type 2 narcolepsy patients. 35 Previously, we have reported that serum levels of brain-derived neurotrophic factor (BDNF) were significantly increased in narcolepsy patients. 36 Others have found decreased serum levels of BDNF in insomnia patients with restless legs syndrome, periodic limb movement, subthreshold insomnia, fatigue, and tiredness. 37, 38 Furthermore, BDNF was increased after acute sleep loss but decreased in chronic sleep deprivation. 39 Accordingly, sleep homeostasis may be linked to the neurotrophic actions of BDNF on synaptic plasticity, neurogenesis, and neuronal survival in the brain. [40] [41] [42] The aim of the current study was to investigate whether six neurodegeneration biomarkers were altered in CSF samples from narcolepsy and hypersomnia patients with disease duration of 2-29 years. We measured the CSF levels of β-amyloid, T-tau, P-tau181, α-synuclein, NF-L, and CHI3L1 in a well-characterized group of patients with type 1 narcolepsy, type 2 narcolepsy, and idiopathic hypersomnia in comparison with healthy controls.
METHODS

Ethics Statement
After approval (KA03119 and H-1-2011-019) from the Danish Health Science Ethical Committee (Capital Region) and obtaining written informed consent, CSF was collected from Danish patients with various hypersomnias and healthy controls seen at the Danish Center for Sleep Medicine and the Department of Neurology, Rigshospitalet, University of Copenhagen, Denmark.
Study Subjects
The patients were recruited for our recent studies of microRNAs in plasma and CSF. 43, 44 Samples from 21 patients diagnosed with central hypersomnia were analyzed in the present study, including ten type 1 narcolepsy patients, five type 2 narcolepsy patients, and six idiopathic hypersomnia patients. The diagnosis was based on International Classification of Sleep Disorders criteria. 13 All patients were examined at the Danish Center for Sleep Medicine, Rigshospitalet, Denmark. Exclusion criteria were the presence of neurological, psychiatric, or medical disorders. Furthermore, patients were free of drugs including antidepressants, anticonvulsants, and stimulants 7-14 days before inclusion. Patients were evaluated by neurological examination, PSG, multiple sleep latency test, CSF hypocretin-1 levels, and HLA-typing of the DQB1*06:02 locus. HLA typing and hypocretin-1 assay measurements have been described previously. 43 Their sleep history was obtained by a semistructured interview based on the Stanford Sleep Questionnaire. Twelve healthy controls were included in the study after recruitment by the Department of Neurology, Rigshospitalet, as part of a larger group of healthy individuals selected from the general population based on age and gender through a Web portal for research study volunteers. 45 None had a history or symptoms of autoimmune, neurological, sleep, or chronic disorder. They underwent a thorough clinical and neurological examination, assay of CSF hypocretin-1 levels, and HLA-typing of the DQB1*06:02 locus. Patients and controls in the study were Caucasian.
CSF Sampling for Measurement of Biomarkers of Neurodegeneration
Preanalytical procedures have a significant impact on the stability of CSF biomarkers of neurodegeneration. 46 Specifically, T-tau and P-tau181 levels in CSF seemed to be susceptible to repeated freeze-thaw cycles, delayed storage, and raised temperatures. 47 Furthermore, β-amyloid concentration in CSF decreased after serial tube transfer due to protein absorption. 48 The α-synuclein concentration in CSF decreased after repeated freeze-thawing of samples due to protein aggregation (L. Ø. Pedersen, unpublished). However, others have reported that the α-synuclein ELISA assay from Covance (Princeton, NJ, USA) was not influenced by preanalytical confounders, including the need for centrifugation of freshly drawn CSF, delayed freezing, volume of storage aliquots, freeze/thaw cycles, and thawing conditions. 49 CSF concentrations of NF-L and CHI3L1 (~YKL-40) showed low assay variability and did not change with up to 3 freeze-thaw cycles, delayed freezing, and raised temperatures (S. Modvig, unpublished). 45, 50 To minimize the impact of preanalytical confounding factors on the CSF biomarker assays, a strict protocol was followed for handling CSF samples from patients and healthy controls. CSF was collected between 8:00 and 12:00 am, immediately cooled on ice, and 1-mL aliquots were stored at −80°C. Before analysis, CSF samples were centrifuged at 400 g for 5 min to remove cell and protein debris. β-amyloid, T-tau, P-tau181, and α-synuclein were analyzed in samples stored at −80 ºC that had not been previously thawed. NF-L and CHI3L1 were analyzed in samples that had been thawed and frozen once.
Measurement of CSF β-Amyloid, T-Tau, and P-Tau181
Human β-amyloid in CSF was determined with the Innotest® β-amyloid(1-42) enzyme-linled immunosorbent assay (ELISA) from Fujirebo Europe. Human T-tau in CSF was determined with Innotest® h-Tau ELISA. Human P-tau181 in CSF was determined with Innotest® phospho-Tau(181P) ELISA. β-amyloid was measured with a standard curve in the range 125-2000 ng/L, T-tau in the range 45-1200 ng/L, and P-tau181 in the range 15-500 ng/L. Standard curves were fitted to a four-parameter sigmoid curve, as recommended by the manufacturer. High and low kit controls and in-house control samples were used to monitor the performance of the ELISA. The interassay coefficient of variation (CV) of the assays was less than 15%.
Measurement of CSF α-Synuclein
Human α-synuclein in CSF was determined with the Meso Scale Discovery (MSD) Multi-array® electrochemiluminescence immunoassay utilizing plates precoated with capture antibodies. The sample and MSD Sulfo-Tag TM detection antibody conjugated with electrochemiluminescent label were added. The intensity of the emitted light provided a quantitative measure of α-synuclein in the sample. The intraassay CV was estimated to be <5% in each assay.
Measurement of CSF NF-L and CHI3L1
Human NF-L in CSF was determined with NF-Light® ELISA from UmanDiagnostics (Umeå, Sweden). Human CHI3L1 in CSF was determined with Human Chitinase 3-like 1 Quantikine ELISA from R&D systems (Abingdon, United Kingdom). Mean intraassay variations were 2.2% for NF-L and 3.1% for CHI3L1. NF-L samples were run on the same plate. The interassay CV for CHI3L1 was 3.4%, as calculated by an internal quality control of pooled CSF.
Statistical Procedures
The β-amyloid, T-tau, P-tau181, α-synuclein, and NF-L and CHI3L1 concentrations in CSF were normally distributed (D'Agostino and Pearson omnibus normality test). Hence, between-group differences for α-synuclein, β-amyloid, T-tau, NF-L, and CHI3L1 concentrations in CSF were evaluated for statistical significance by one-way analysis of variance (ANOVA) of the log-transformed data. Intergroup comparison was performed using Tukey's Multiple Comparison Test. To compare means, levels of analytes below the lower limit of quantification were set to the lowest value of the standard curve (for P-tau181 15.6 pg/mL). Group differences in demographic variables (except for gender) were compared with the Kruskal-Wallis or Wilcoxon Rank-Sum test or by analysis of covariance because they were not normally distributed (D'Agostino and Pearson omnibus normality test).
RESULTS
Patient Demographics
The demographic characteristics of the patients and the controls are summarized in Table 1 . Patients with type 1 narcolepsy were 100% HLA DQB1*06:02-positive, had a low or undetectable concentration of hypocretin-1 (< 110 pg/mL) in the CSF, and had typical cataplexy (triggered by emotions). Patients with type 2 narcolepsy and those with idiopathic hypersomnia had a normal concentration of hypocretin-1 (≥ 200 pg/mL) in the CSF, were 40% and 33% HLA DQB1*06:02-positive, respectively, and had no cataplexy. Twelve healthy controls had a normal CSF concentration of hypocretin-1 (414.2 ± 20.8 pg/mL) and were 25% HLA DQB1*06:02-positive in agreement with a previous study. 16 Cases and controls were matched for body mass index (BMI). The mean age of patients and controls was 33 years and 32 years, respectively.
CSF β-Amyloid, T-Tau, and P-Tau181
The CSF β-amyloid, T-tau, and P-tau181 results are shown in Figure 1 . There were significant differences between the CSF levels of the three AD biomarkers in the four groups ( Table 2 ). The type 1 narcolepsy group had significantly lower levels of β-amyloid, T-tau, and P-tau181 compared to healthy controls (p < .05). T-tau and P-tau181 levels were significantly lower in type 1 narcolepsy than in the idiopathic hypersomnia group (p < .05). Moreover, CSF β-amyloid levels in the type 2 narcolepsy group also differed significantly from those of the healthy control group (p < .05). The lower levels of β-amyloid, T-tau, and P-tau181 in CSF were confirmed by measurements of a second set of CSF samples from the same four groups of patients and controls (data not shown). The mean values of β-amyloid, T-tau, and P-tau181 concentrations in CSF from controls were 698, 162, and 34 pg/mL, respectively, which are similar to the values of previous studies. 23 No relationship was found between CSF β-amyloid, T-tau, and P-tau181 concentrations and subject's age or sex (data not shown).
CSF α-Synuclein
A plot of the CSF α-synuclein results is shown in Figure 2 . The CSF α-synuclein concentrations ranged from 100 to 300 pg/mL, which are similar to those of other studies. 24 The mean values were 158-203 pg/mL, and there were no significant differences between the α-synuclein levels in the four groups (Table 2) . One type 1 narcolepsy patient with α-synuclein of 825 pg/mL was removed as an outlier, which deviated by more than 3.3 SD from the mean. The exclusion of this case did not substantively change the results. No relationship was found between CSF α-synuclein concentration and subject's age and sex (data not shown).
CSF NF-L and CHI3L1
The CSF NF-L and CHI3L1 results are shown in Figure 3 . The NF-L concentrations of 100-600 ng/L and CHI3L1 concentrations of 30-170 ng/mL in CSF were similar to the previous observations. 25, 26 The mean values of NF-L were 220-311 ng/ mL, and there were no significant differences between the four groups ( Table 2) . One type 1 narcolepsy patient with NF-L of 925 ng/mL was removed as an outlier, which deviated by more than 3.3 SD from the mean. The exclusion of this case did not substantively change the results. The mean values of CHI3L1 levels in the four groups were 72-82 ng/mL with no significant differences ( Table 2) . No relationship was found between CSF NF-L and CHI3L1 concentrations and subject's age and sex (data not shown).
DISCUSSION
In the present study, we measured the CSF concentration of six biomarkers of neurodegeneration: β-amyloid, T-tau, and P-tau181, α-synuclein, NF-L, and CHI3L1 in patients with type 1 narcolepsy, type 2 narcolepsy, and idiopathic hypersomnia. The patients were aged 33 years on average (range 16-53 years), were moderate overweight (BMI 24-27), were free of medicine for 1-2 weeks, and had a disease duration of 2-29 years. CSF levels of β-amyloid were significantly lower in type 1 and type 2 narcolepsy than in healthy controls. In addition, the concentration of T-tau and P-tau181 in CSF was lower in type 1 narcolepsy patients than in idiopathic hypersomnia and controls. Our study showed that the CSF concentration of α-synuclein was not significantly different in type 1 and type 2 narcolepsy compared to controls. Furthermore, CSF levels of NF-L and CHI3L1 showed no significant differences between narcolepsy cases and healthy controls. We interpret our findings that taupathies, and α-synucleinopathy, as well as the neuronal damage and glial activation seen during inflammation in MS are not involved in the pathogenesis and phenotype of narcolepsy. Type 1 narcolespy is caused by autoimmunity-mediated destruction of hypocretin nerve cells in the hypothalamus and hypocretin axons projecting to several brain regions followed by increased gliosis in the brain of narcoleptic patients. 51, 52 After the initial phase of the disease with inflammation, healing and scarring the disease seems to be in a stable phase with no further progression. 53 However, one report showed that AD occurred in narcoleptic patients with approximately normal incidence, although further large epidemiological studies would be useful. 54 Sleep disturbances occur frequently in AD patients and are associated with the severity of dementia. 29 The neurodegenerative process of AD may affect the hypothalamic hypocretin neurons as reflected in a 40% decreased hypocretin cell number and 14% lower CSF hypocretin-1 levels in advanced AD. 55 Conversely, disturbed wake-sleep cycle may promote the development of AD based on the observation that high levels of β-amyloid in brain ISF during wakefulness correlate with the increased levels of hypocretin-1.
11,31 Thus, CSF hypocretin-1 levels were higher in patients with AD and MCI compared to other dementias. 32, 33 Furthermore, the wake-active amine, histamine, may be of importance in the pathophysiology of narcolepsy, since recent work has identified a major increase in the number of histamine cells in the tuberomammillary nucleus (TMN) in the brain of human narcoleptics. 56, 57 However, the CSF levels of histamine were decreased in narcolepsy, which may contribute to the daytime sleepiness in these patients. 58, 59 The increase in the histaminergic neurons may be compensatory to the loss of hypocretinergic neurons, which densely innervate TMN and activate the histaminergic neurons.
Our study is in agreement with a previous study that reported lower CSF level of β-amyloid in type 1 and type 2 narcolepsy, whereas those of T-tau and P-tau181 did not differ from the levels in controls. 34 Recently, the same group confirmed the low β-amyloid level in CSF of type 1 narcolepsy patients with short disease duration <5 years and long disease duration >5 years. However, the level of P-tau181 was increased in patients with long disease duration compared to short disease duration and controls. 60 Furthermore, they have previously suggested that CSF β-amyloid and tau proteins levels in narcolepsy may be influenced by long treatment duration and stable medication. 61 Another group observed higher concentrations of β-amyloid, T-tau, and P-tau181 as well as neuron-specific enolase in CSF of patients with type 1 and type 2 narcolepsy in comparison with healthy controls. 35 The discrepancies between the results in these studies may be explained by differences in the patient demographics such as age, duration of disease, and medication, since the CSF concentration of T-tau and P-tau181 are dependent on these parameters. 20, 60, 61 Our finding of lower CSF β-amyloid levels in narcolepsy patients may be explained by an altered turnover of β-amyloid in the brain due to either lower production or higher clearance. We propose that three factors could be involved in the pathophysiological regulation of β-amyloid action and metabolism in narcolepsy: lack of hypocretin, unstable sleep-wake cycle, and increased BDNF in the brain. First, the absence of hypocretin neurons in type 1 narcolepsy may result in lower β-amyloid production during the frequent sleep-wake transitions. The role of the sleep-wake cycle in regulation of the β-amyloid production has been investigated in mice and humans. 12 The concentration of β-amyloid in ISF from the hippocampus of mice showed a pronounced diurnal rhythm with high β-amyloid levels during the awake state and low levels during sleep. The amount of ISF β-amyloid increased during hypocretin infusion and decreased following infusion of a hypocretin receptor antagonist in mice, indicating that hypocretin release during wakefulness is associated with increased β-amyloid production. 11, 12 Diurnal oscillations in CSF β-amyloid levels observed in humans were similar to those in the ISF of mice, although the phase was delayed by approximately 6 hours, presumably because of the transit time of β-amyloid from the ISF to the lumbar CSF compartment. 12 Second, the unstable sleep-wake cycle in type 1 narcolepsy with daytime sleep, frequent transitions between sleep and wakefulness, short sleep latency, and rapid entry into REM sleep may lead to increased clearance of β-amyloid from the brain through the glymphatic system. The glymphatic system has recently been characterized as CSF circulation throughout the entire brain, which is involved in the clearance of metabolites and proteins, including β-amyloid. [6] [7] [8] [9] Natural sleep and anesthesia of mice were associated with a striking increase in the rate of β-amyloid clearance. 5 Sleeping and anesthetized mice cleared injected 125 I-labelled β-amyloid twice as fast as do awake mice. During awakening, the flow of CSF through T-tau, and (C) P-tau181 were determined by Innotest® ELISA and the concentration (pg/mL) plotted for each patient group: type 1 narcolepsy (Type 1 NC; n = 10), type 2 narcolepsy (Type 2 NC; n = 5), idiopathic hypersomnia (IH; n = 6) and healthy controls (HC; n = 12). the brain interstitial space was reduced to only 5% of the flow during sleep. 5 Finally, transport of biomarkers after traumatic brain injury in mice to the blood via the glymphatic system, was suppressed by sleep deprivation. 62 Third, the increased level of BDNF in type 1 narcolepsy 36 may have a role in the regulation of β-amyloid metabolism in the brain. The brain is the primary contributor to blood BDNF levels as shown by differences in relative BDNF levels in the cerebral artery and internal jugular vein after exercise, and a positive correlation between BDNF in brain and blood of pig and rat. 63, 64 BDNF is involved in synaptic plasticity, neurogenesis, and neuronal survival in the brain. 41 Several studies have shown that BDNF exerted protective effects against β-amyloid-induced neurotoxicity in rat neuronal cell cultures and rat brain. [65] [66] [67] [68] In humans, BDNF and soluble β-amyloid levels in postmortem brain correlated with AD and dementia in the oldest-old subjects >90 years. 69 However, BDNF regulation of β-amyloid production or clearance has not yet been demonstrated. Our study showed that the CSF concentration of α-synuclein, NF-L, and CHI3L1 was not significantly different in type 1 and type 2 narcolepsy compared to healthy controls. Regulation of release or clearance by hypocretin of these proteins in the brain has not been reported. Furthermore, α-synuclein clearance in the brain involved intracellular proteolysis via the autophagy lysosomal pathway. 70, 71 α-synuclein clearance via the glymphatic system has not been investigated. So far increased clearance of NF-L in CSF has only been shown in patients with mild traumatic brain injury. 72 The are some limitations to the present study including the relatively small number of patients, the unknown significance of neurodegeneration biomarkers in narcolepsy, and the correlational nature of the findings. First, the number of patients and controls was limited to 33 individuals to analyze the three groups of central hypersomnia patients and search for differences and similarities between the sleep disorders in comparison to controls. In spite of the small number of patients, we were able to identify statistically significant changes in the CSF levels of three neurodegeneration biomarkers linked to AD. Second, the role of β-amyloid, T-tau, and P-tau181 in the pathophysiology of narcolepsy is difficult to ascertain, given their unknown origin, function, or targets in central nervous system (CNS). Third, the biomarker changes in narcolepsy patients are correlational. At present, we cannot link the biomarkers to the pathophysiology of sleep disorders, but they give clues about abnormalities in the CNS.
In conclusion, our finding that patients with narcolepsy exhibit decreased or normal levels of neurodegeneration biomarkers, β-amyloid, T-tau, P-tau181, α-synuclein, NF-L, and CHI3L1, indicate that taupathies, synucleinopathies, and ongoing glial activation with neuronal destruction are not prevalent in narcolepsy. Accordingly, narcolepsy patients with a disease duration of 2-29 years seem to be in a stable phase of their disease with no progression and neurodegeneration. The pathophysiological mechanism behind the lower CSF levels of β-amyloid, T-tau, and P-tau181 in type 1 narcolepsy is not clear. However, we speculate that the hypocretin deficiency in narcolepsy may reduce β-amyloid release during awakenings and that the abnormal sleep-wake pattern in narcolepsy patients may increase β-amyloid, T-tau, and P-tau181 clearance in the brain. Finally, increased BDNF levels in type 1 narcolepsy patients may have a protective effect against β-amyloid-induced neurotoxicity.
